Matthew Weston
Stock Analyst at UBS
(4.25)
# 1,455
Out of 4,703 analysts
364
Total ratings
66.7%
Success rate
10%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €62.00 | €48.84 | +26.95% | 24 | Sep 1, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | CHF 124.84 | -7.08% | 48 | Sep 1, 2026 | |
| ETR: MRK Merck KGaA | Downgraded: Hold | €150.00 | €134.45 | +11.57% | 38 | Aug 20, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Upgraded: Buy | €240.00 → €300.00 | €231.10 | +29.81% | 30 | Aug 20, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Upgraded: Buy | €220.00 → €260.00 | €185.30 | +40.31% | 17 | Aug 20, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | kr 303.71 | +9.31% | 28 | Aug 5, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | 12,114p | +45.29% | 68 | Aug 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 → €78.00 | €75.49 | +3.32% | 16 | Jul 31, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | CHF 157.45 | +27.02% | 12 | Jul 24, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,940p | 1,836p | +5.66% | 18 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 376.00 | CHF 351.60 | +6.94% | 55 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $150.33 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | CHF 558.80 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €165.10 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $46.60 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $159.99 | n/a | 1 | Jul 5, 2017 |
Bayer Aktiengesellschaft
Sep 1, 2026
Maintained: Buy
Price Target: €62.00
Current: €48.84
Upside: +26.95%
Novartis AG
Sep 1, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: CHF 124.84
Upside: -7.08%
Merck KGaA
Aug 20, 2026
Downgraded: Hold
Price Target: €150.00
Current: €134.45
Upside: +11.57%
Sartorius Aktiengesellschaft
Aug 20, 2026
Upgraded: Buy
Price Target: €240.00 → €300.00
Current: €231.10
Upside: +29.81%
Sartorius Stedim Biotech S.A.
Aug 20, 2026
Upgraded: Buy
Price Target: €220.00 → €260.00
Current: €185.30
Upside: +40.31%
Novo Nordisk A/S
Aug 5, 2026
Maintained: Hold
Price Target: kr 332.00
Current: kr 303.71
Upside: +9.31%
AstraZeneca PLC
Aug 4, 2026
Maintained: Buy
Price Target: 17,600p
Current: 12,114p
Upside: +45.29%
Sanofi
Jul 31, 2026
Maintained: Hold
Price Target: €88.00 → €78.00
Current: €75.49
Upside: +3.32%
Galderma Group AG
Jul 24, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: CHF 157.45
Upside: +27.02%
GSK plc
Jul 13, 2026
Maintained: Hold
Price Target: 1,940p
Current: 1,836p
Upside: +5.66%
May 13, 2026
Maintained: Buy
Price Target: CHF 376.00
Current: CHF 351.60
Upside: +6.94%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $150.33
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: CHF 558.80
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €165.10
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $46.60
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $159.99
Upside: n/a